Related Experiment Video

Updated: Apr 30, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Casticin induces breast cancer cell apoptosis by inhibiting the expression of forkhead box protein M1

Li-Ping Liu1, Xiao-Cheng Cao2, Fei Liu2

  • 1The Breast Department, Hunan Province Tumor Hospital, Changsha, Hunan 410013, P.R. China.

Oncology Letters
|April 26, 2014
PubMed

Insights

Casticin, from traditional Chinese medicine, induces breast cancer cell death by activating FOXO3a. This key protein, forkhead box O3 (FOXO3a), mediates casticin

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Casticin is a bioactive compound from Fructus Viticis, a traditional Chinese medicine.
  • Breast cancer remains a significant health concern, necessitating novel therapeutic strategies.
  • Understanding molecular pathways involved in cancer cell apoptosis is crucial for drug development.

Purpose of the Study:

  • To investigate the role of forkhead box O3 (FOXO3a) in breast cancer cells.
  • To elucidate the regulatory mechanisms of FOXO3a in response to casticin treatment.
  • To assess the therapeutic potential of casticin in breast cancer.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA)
  • Flow cytometry
  • Small interfering RNA (siRNA) transfection
  • Western blot analysis

Main Results:

  • Casticin treatment induced apoptosis in breast cancer cells.
  • Casticin reduced the expression of transcription factor forkhead box protein M1 (FOXM1).
  • FOXM1 repression correlated with increased dephosphorylation and activation of FOXO3a.
  • Silencing FOXO3a attenuated casticin-induced apoptosis, confirming its critical role.

Conclusions:

  • FOXO3a is a critical mediator of casticin's apoptotic effects in breast cancer cells.
  • Casticin may represent a promising therapeutic agent for breast cancer treatment.
  • The casticin-FOXO3a pathway warrants further investigation for targeted cancer therapies.
Keywords:
breast cancercasticinforkhead box O3forkhead box protein M1therapeutic targets

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K